US Stock Futures Edge Lower Ahead Of Jobless Claims Data - Acura Pharmaceuticals (OTC:ACUR)

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

Pre-open moversUS stock futures fell in early pre-market trading. Data on weekly jobless claims and import prices for March will be released at 8:30 a.m. ET, while the Federal Open Market Committee will issue minutes of its latest meeting at 2:00 p.m. ET. Futures for the Dow Jones Industrial Average tumbled 17 points to 16,343.00, while the Standard & Poor's 500 index futures fell 1.90 points to 1,862.90. Futures for the Nasdaq 100 index dropped 5 points to 3,586.00.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

A Peek Into Global Markets European markets were mostly lower today, with the Spanish Ibex Index dropping 1.06%, London's FTSE 100 index gaining 0.08% and STOXX Europe 600 Index slipping 0.25%. German DAX 30 index dropped 0.16% and French CAC 40 Index fell 0.25%. French industrial production climbed 0.1% in February versus January, while the consumer price index gained 0.4% in March versus February.Asian markets ended mostly higher today. Japan's Nikkei Stock Average rose 0.43 points, Hong Kong's Hang Seng Index gained 1.51%, China's Shanghai Composite surged 1.38% and India's BSE Index jumped 0.06%. Broker Recommendation

Analysts at Bank of America downgraded Bed Bath & Beyond (NASDAQ: BBBY) from “buy” to “neutral.” The target price for Bed Bath & Beyond has been lowered from $87 to $72. Bed Bath & Beyond's shares closed at $67.91 yesterday. Breaking news

Costco Wholesale (NASDAQ: COST) reported a 5% gain in its total same-store sales for the five-week period ended April 6. To read the full news, click here.
Rite Aid (NYSE: RAD) reported better-than-expected fiscal fourth-quarter net income. Rite Aid's quarterly net profit fell to $55.4 million, or $0.06 per share, versus a year-ago profit of $123.1 million, or $0.13 per share. To read the full news, click here.
Acura Pharmaceuticals (NASDAQ: ACUR) announced today a letter agreement with Pfizer Inc. providing for the termination of Pfizer's (NYSE: PFE) license to Acura's AVERSION Technology and the return to Acura of the FDA approved Oxecta product. To read the full news, click here.
Merck (NYSE: MRK) today announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). To read the full news, click here.